Regenxbio (RGNX) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75901B1070

(NASDAQ:RGNX Stock) REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Regenxbio (RGNX) - Stock Price & Dividends

RGNX Stock Overview

Market Cap in USD 546m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2015-09-17

RGNX Stock Ratings

Fundamental -7.52
Dividend -
Growth 5y -5.94
Rel. Performance vs Sector -3.13
Analysts 4.20
Fair Price Total Ret. 13.70
Fair Price DCF -

RGNX Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

RGNX Growth Ratios

Growth 12m -18.30%
Growth Correlation 12m -47%
Growth Correlation 3m -48%
CAGR 5y -20.21%
CAGR / Mean Drawdown -0.41
Sharpe Ratio 12m -0.40
Alpha vs SP500 12m -59.33
Beta vs SP500 5y weekly 1.44
CAPM 9.23%
Average Daily Range 2m 7.47%
Regime Oscillator 89.08
Volatility GJR Garch 1y 64.49%
Price / SMA 50 7.2%
Price / SMA 200 -1.53%
Current Volume 698.2k
Average Volume 20d 752.4k

External Links for RGNX Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of RGNX stocks?
As of February 24, 2024, the stock is trading at USD 17.41 with a total of 698,174 shares traded.
Over the past week, the price has changed by -7.54%, over one month by +22.69%, over three months by -10.72% and over the past year by -19.77%.
Why is RGNX stock down?
Check with which Index or Commodity RGNX has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return RGNX Return S&P 500
1 Month 22.69% 4.74%
3 Months -10.72% 11.99%
12 Months -19.77% 28.68%
What is the forecast for RGNX stock price target?
According to ValueRays Forecast Model, RGNX Regenxbio will be worth about 15.1 in February 2025. The stock is currently trading at 17.41. This means that the stock has a potential downside of -13.38%.
Issuer Forecast Upside
Wallstreet Target Price 34.7 99.3%
Analysts Target Price 41.6 138.7%
ValueRay Target Price 15.1 -13.4%